Autopsy report · NCT01532362

Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer

“Drug sponsor stopped drug manufacture due to toxicity issues from other studies”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 6 months before it stopped.
• 1 participant enrolled.
• Results were posted on the registry 3 years 9 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Jonsson Comprehensive Cancer Center

Sponsor type

University, hospital or other

Conditions

Non Small Cell Lung Cancer

Interventions

Apricoxib

Participants

1

Sites

1

Countries

United States

Trials that died the same way

• A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
  “The Sponsor terminated the study due to early dose-limiting toxicities.” (79% match in meaning)
• Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes
  “Drug no longer being supplied by sponsor” (77% match in meaning)
• Vorinostat and Concurrent Whole Brain Radiotherapy for Brain Metastasis
  “Sponsor stops to provide the study drug.” (74% match in meaning)
• Study of Satraplatin (JM-216) in Combination With Docetaxel
  “Sponsor decided to discontinue study drug development.” (74% match in meaning)
• A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea
  “Sponsor's decision for the Drug Development.” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.